Lipid-based nanoformulations of trifluralin analogs in the management of Leishmania infantum infections

Hemisynthetic trifluralin analogues incorporated in liposomes for the treatment of leishmanial infections

(2015) Manuela Carvalheiro et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Liposomes versus Lipid Nanoparticles: Comparative Study of Lipid-Based Systems as Oryzalin Carriers for the Treatment of Leishmaniasis

(2014) R. M. Lopes et al.   Journal of Biomedical Nanotechnology

A novel alkyl phosphocholine-dinitroaniline hybrid molecule exhibits biological activity in vitro against Leishmania amazonensis

(2013) Joseane Lima Prado Godinho et al.   EXPERIMENTAL PARASITOLOGY

Evaluation of the growth-inhibitory effect of trifluralin analogues on in vitro cultured Babesia bovis parasites

(2013) Marta G. Silva et al.   International Journal for Parasitology-Drugs and Drug Resistance

Formulation of oryzalin (ORZ) liposomes: In vitro studies and in vivo fate

(2012) Rui M. Lopes et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Leishmaniasis: new insights from an old and neglected disease

(2011) S. Antinori et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Selenocyanates and diselenides: A new class of potent antileishmanial agents

(2011) Daniel Plano et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Lipid nanoparticles containing oryzalin for the treatment of leishmaniasis

(2011) R. Lopes et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Leishmania Mitochondrial Peroxiredoxin Plays a Crucial Peroxidase-Unrelated Role during Infection: Insight into Its Novel Chaperone Activity

(2011) Helena Castro et al.   PLoS Pathogens

The size of solid lipid nanoparticles: An interpretation from experimental design

(2010) Carla Vitorino et al.   COLLOIDS AND SURFACES B-BIOINTERFACES

Synthesis and biological evaluation of trifluralin analogues as antileishmanial agents

(2009) M.A. Esteves et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Leishmaniasis: Current Treatment and Prospects for New Drugs and Vaccines

(2009) Lukasz Kedzierski et al.   CURRENT MEDICINAL CHEMISTRY

Trifluralin liposomal formulations active against Leishmania donovani infections

(2008) Manuela Carvalheiro et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Development of new antileishmanial drugs – current knowledge and future prospects

(2008) Patrice Le Pape   JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Efficacy of the liposome trifluralin in the treatment of experimental canine leishmaniosis

(2007) C. Marques et al.   VETERINARY JOURNAL